Daewoong Pharmaceutical Co Ltd (069620) · Other

LigaChem Biosciences Inc (141080) · Other

Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.

6/4/2026, 12:00:00 AM

Chong Kun Dang Pharm Co (185750) · Other

The company's natural new drug for gastritis, 'Zitec', is scheduled to receive conditional reimbursement approval from the Health Insurance Review and Assessment Service's (HIRA) drug evaluation committee on June 4, 2026, provided the company accepts a price below the evaluated amount. Estimated price impact >=5% as this is a critical step for market entry scheduled.

6/4/2026, 12:00:00 AM

ABL Bio Inc (298380) · Other

ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.

6/4/2026, 12:00:00 AM

Peptron Inc (087010) · Other

Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.

6/2/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Other

Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.

6/1/2026, 12:00:00 AM

Voronoi Inc (310210) · Other

Voronoi presented positive clinical trial data for VRN11 at ASCO 2026 on June 1, 2026. High importance is estimated due to strong anti-tumor response in brain metastases, a major unmet need, scheduled.

6/1/2026, 12:00:00 AM